Stryker Corporation
NYSE:SYKMedical - Devices
+$9.29 today
- Market cap
- $121.12B
- Beta
- 0.79
- P/E (TTM)
- 35.6
- EPS (TTM)
- $8.72
- Dividend yield
- 1.11%
Volume 3.25M
Average 2.49M
SYK EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Stryker CorporationNYSE: SYK
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA grows, but more slowly than its trailing trend
Q2 FY2026 EBITDA of $2B rose 23.7% year over year, behind the +40.7% change in trailing-twelve-month EBITDA. Sequentially, it rose 54.2% from the prior quarter. Over 3 fiscal years it compounded at +16.3% a year.
Context
- EBITDA amounted to 25.1% of revenue in FY2025, down 1.4 pp from a year earlier.
- EBITDA increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 20 analysts of $8.34B (+32.1%) for the fiscal year ending Dec 2026, a step up from the +5.1% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- $2B+54.2% QoQ
- Last fiscal yearDec 2025
- $6.31B+5.1% YoY
- LTMJun 2026
- $6.69B+40.7% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +23.7% | +41.1% | +17.4 pp |
| 1 year | +5.1% | +32.1% | +26.9 pp |
| 3-year CAGR | +16.3% | +15.5% | -0.7 pp |
| 5-year CAGR | +12.5% | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- 6.31B USD
- Year-over-year change
- +5.1%
- 4-year CAGR
- +15.0%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 6.31B | +5.1% |
| FY2024 | 2024-12-31 | 6.01B | +18.8% |
| FY2023 | 2023-12-31 | 5.06B | +25.9% |
| FY2022 | 2022-12-31 | 4.02B | +11.4% |
| FY2021 | 2021-12-31 | 3.61B | — |
EBITDA vs competitors
How SYK compares with its peers on the latest reported figures
- SYK's LTM Jun 2026 EBITDA of $6.69B is the 2nd highest of the 11 companies compared; the peer median is $132.07M.
- Its year-over-year change of +40.7% is the 5th highest of 11, against a peer median of +6.3%.
- EBITDA amounts to 25.9% of revenue for SYK, versus a peer median of 19.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jul 2026 | $10.27B | +9.8% | +4.1% | 27.3% | |
| LTM Jun 2026 | $6.69B | +40.7% | +16.3% | 25.9% | |
| LTM Jun 2026 | $2.34B | +2.7% | +14.1% | 27.5% | |
| FY2025 | $1.34B | +0.1% | +5.1% | 21.7% | |
| LTM Jun 2026 | $945.76M | +52.8% | +42.8% | 30.1% | |
| LTM Mar 2026 | $169.63M | -31.6% | +170.6% | 12.4% | |
| LTM Mar 2026 | $94.51M | +693.8% | — | 11.5% | |
| LTM Mar 2026 | $11.81M | +465.2% | — | 9.7% | |
| LTM Mar 2026 | -$1.36M | +97.4% | — | 0.2% | |
| LTM Mar 2026 | -$289.3M | -260.5% | — | 17.6% | |
| LTM Apr 2026 | -$748.33M | -58.6% | — | 32.8% | |
| Peer median (excluding SYK) | $132.07M | +6.3% | +14.1% | 19.6% | |
Competitors are the stored peer set for SYK. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 17.11B | 18.45B | 20.5B | 22.6B | 25.12B |
| Cost of Revenue | 6.4B | 7.41B | 8B | 8.05B | 9.05B |
| Gross Profit | 10.71B | 11.04B | 12.49B | 14.55B | 16.07B |
| Gross Margin | 62.6% | 59.8% | 61.0% | 64.4% | 64.0% |
| Research & Development | 1.13B | 1.23B | 1.29B | 1.47B | 1.58B |
| Selling, General & Admin | 5.81B | 6.08B | 6.92B | 7.5B | 8.65B |
| Operating Expenses | 6.95B | 7.31B | 8.21B | 10.86B | 11.18B |
| Depreciation & Amortization | 990M | 998M | 1.03B | 1.05B | 1.19B |
| EBITDA | 3.61B | 4.02B | 5.06B | 6.01B | 6.31B |
| EBITDA Margin | 21.1% | 21.8% | 24.7% | 26.6% | 25.1% |
| Operating Income | 3.76B | 3.73B | 4.28B | 3.69B | 4.89B |
| Operating Margin | 22.0% | 20.2% | 20.9% | 16.3% | 19.5% |
| Interest Income | 68M | 94M | 75M | 139M | 121M |
| Interest Expense | 337M | 337M | 356M | 396M | 607M |
| Other Income / Expenses | (1.48B) | (1.05B) | (608M) | (197M) | (375M) |
| Income Before Tax | 2.28B | 2.68B | 3.67B | 3.49B | 4.51B |
| Pre-Tax Margin | 13.3% | 14.5% | 17.9% | 15.5% | 18.0% |
| Income Tax Expense | 287M | 325M | 508M | 499M | 1.27B |
| Net Income | 1.99B | 2.36B | 3.17B | 2.99B | 3.25B |
| Net Margin | 11.7% | 12.8% | 15.4% | 13.2% | 12.9% |
| EPS (Basic) | 5.29 | 6.23 | 8.34 | 7.86 | 8.49 |
| EPS (Diluted) | 5.22 | 6.17 | 8.25 | 7.76 | 8.40 |
| Weighted Avg Shares | 377M | 378.2M | 379.6M | 381M | 382.2M |
| Weighted Avg Shares (Diluted) | 382.3M | 382.2M | 383.7M | 385.6M | 382.2M |
Stryker Corporation
NYSE:SYK
Intrinsic Alpha fair value
Locked
Current Price
$318.15
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.